Contributors

Syed F. Ali, PhD • Neurochemistry Laboratory, Division of Neurotoxicology, National

Center for Toxicological Research, Food and Drug Administration, Jefferson, AR David A. Baker, PhD • Department of Physiology and Neuroscience, Medical School of South Carolina, Charleston, SC Howard C. Becker, PhD • Charleston Alcohol Research Center, Center for Drug and Alcohol Programs, Department of Psychiatry and Behavioral Sciences, Physiology, and Neuroscience, Department of Veterans Affairs Medical Center, Medical University of South Carolina, Charleston, SC Adam Bisaga, md • Division on Substance Abuse, Department of Psychiatry, Columbia

University College of Physicians and Surgeons, New York, NY Karin Borges, PhD • Department of Pharmacology, Emory University School of Medicine, Atlanta, GA

Kristan B. Burrows, PhD • Program in Basic and Clinical Neuroscience, Department of Psychiatry, Case Western Reserve University Medical School, Cleveland, OH Jean Lud Cadet, md • Molecular Psychiatry Division, National Institute on Drug

Abuse, National Institutes of Health, Baltimore, MD Larry D. Calder, PhD • Department of Pharmacology, University of Utah School of Medicine, Salt Lake City, UT L. Judson Chandler, PhD • Department of Physiology/Neuroscience and Psychiatry,

Medical University of South Carolina, Charleston, SC Dennis W. Choi, md, PhD • Center for the Study of Nervous System Injury and Department of Neurology, Washington University School of Medicine, St. Louis, MO Jennifer L. Cornish, PhD • National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD Fulton T. Crews, PhD • Director, Center for Alcohol Studies, University of North

Carolina at Chapel Hill, Chapel Hill, NC W. Danysz • Merz Co., Frankfurt, Germany

Raymond Dingledine, PhD • Department of Pharmacology, Emory University School of Medicine, Atlanta, GA D. Cyril D'Souza, MD • Department of Psychiatry, Yale University School of Medicine, New Haven, CT; Alcohol Research Center, VA Connecticut Healthcare System, West Haven, CT; and NIAAA Center for the Translational Neuroscience of Alcoholism, Ribicoff Research Facilities, Connecticut Mental Health Center, New Haven, CT

Mark P. Epping-Jordan, PhD • Addex Pharmaceuticals, Institut de Biologie Cellulaire et du Morphologie, Universit de Lausanne, Lausanne, Switzerland Marian W. Fischman, PhD (deceased) • Division on Substance Abuse, Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, NY

Jerry Frankenheim, phd • DNBR, National Institute on Drug Abuse (NIDA), Bethesda, MD Barbara H. Herman, phd • Clinical Medical Branch, Division of Treatment Research and Devlopment, National Institute on Drug Abuse (NIDA), National Instiutes of Health (NIH), Bethesda, MD

Yossef Itzhak, PhD • Department of Psychiatry and Behavioral Sciences, University of Miami School of Medicine, Miami, FL Frances E. Jensen, md • Children's Hospital, Boston, MA, and Harvard Medical School, Boston, MA

Peter W. Kalivas, PhD • Department of Physiology and Neuroscience, Medical School of South Carolina, Charleston, SC Rafal Kaminski, md, PhD • Drug Development Group, Intramural Research Program,

National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD Ralph Karler, PhD • Department of Pharmacology, University of Utah School of Medicine, Salt Lake City, UT

Marcus Kaul, PhD • Center for Neuroscience and Aging, The Burnham Institute, La Jolla, CA

Yuri Kolesnikov, md, PhD • The Laboratory of Molecular Neuropharmacology, Memorial

Sloan-Kettering Cancer Center, New York, NY John H. Krystal, md • Department of Psychiatry, Yale University School of

Medicine, New Haven, CT; Alcohol Research Center, VA Connecticut Healthcare System, West Haven, CT; and NIAAA Center for the Translational Neuroscience of Alcoholism, Ribicoff Research Facilities, Connecticut Mental Health Center, New Haven, CT

Yuen-Sum Lau, PhD • Division of Pharmacology, School of Pharmacy, University of Missouri-Kansas City, Kansas City, MO Stuart A. Lipton, md, PhD • Center for Neuroscience and Aging, The Burnham Institute, La Jolla, CA

Raye Z. Litten, PhD • Division of Clinical and Prevention Research, National Institute on Alcohol Abuse and Alcoholism (NIAAA), Bethesda, MD Jianren Mao, md, PhD • MGH Pain Center, Department of Anesthesia and Critical

Care, Massachusetts General Hospital, Harvard Medical School, Boston, MA Limin Mao, md • Division of Pharmacology, School of Pharmacy, University of MissouriKansas City, Kansas City, MO Julio L. Martin, PhD • Department of Psychiatry and Behavioral Sciences, University of Miami School of Medicine, Miami, FL Graeme Mason, PhD • Department of Psychiatry, Yale University School of

Medicine, New Haven, CT; Alcohol Research Center, VA Connecticut Healthcare System, West Haven, CT; and NIAAA Center for the Translational Neuroscience of Alcoholism, Ribicoff Research Facilities, Connecticut Mental Health Center, New Haven, CT

Rae R. Matsumoto, PhD • Department of Pharmaceutical Sciences, College of Pharmacy,

University of Oklahoma Health Sciences Center, Oklahoma City, OK Ch. Parsons • Merz Co., Frankfurt, Germany

Gavril W. Pasternak, md, PhD • The Laboratory of Molecular Neuropharmacology, Department of Anesthesiology, Memorial Sloan-Kettering Cancer Center, New York, NY

Robert W. Peoples, PhD • Unit on Cellular Neuropharmacology, Laboratory of Molecular and Cellular Neurobiology, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD Agu Pert, PhD • Biological Psychiatry Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, MD

Contributors xvii

Ismene L. Petrakis, md • Department of Psychiatry, Yale University School of Medicine, New Haven, CT; Alcohol Research Center, VA Connecticut Healthcare System, West Haven, CT; and NIAAA Center for the Translational Neuroscience of Alcoholism, Ribicoff Research Facilities, Connecticut Mental Health Center, New Haven, CT

Piotr Popik, md, phd • Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland

Robert M. Post, phd • Biological Psychiatry Branch, National Institute of Mental

Health, National Institutes of Health, Bethesda, MD Adriaan S. Potgieter, md • Marketing and Business Development, European Society of Cardiology

Buddy Pouw, md • Department of Pharmaceutical Sciences, College of Pharmacy,

University of Oklahoma Health Sciences Center, Oklahoma City, OK Luigi Pulvirenti, md • Department of Neuropharmacology, The Scripps Research

Institute, La Jolla, CA G. Rammes • Max-Planck Institute of Psychiatry, Munich, Germany Kurt Rasmussen, phd • Lilly Research Laboratories, Eli Lilly & Co., Lilly Corporate

Center, Indianapolis, IN Nicole Redmond • Charleston Alcohol Research Center, Center for Drug and Alcohol Programs, Department of Psychiatry and Behavioral Sciences, Physiology, and Neuroscience, Department of Veterans Affairs Medical Center, Medical University of South Carolina, Charleston, SC Michael A. Rogawski, md, phd • Epilepsy Research Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD Joseph G. Rudolph, phd • NIH/NIAAA/DICBR/LNG, Rockville, MD Russell M. Sanchez, phd • Children's Hospital, Boston, MA, and Harvard Medical School, Boston, MA

Philip H. Sheridan, md • Division of Neuropharmacological Drug Products, Center for Drug Evaluation and Research, Office of Drug Evaluation I, Food and Drug Administration, Rockville, MD B. Joy Snider, md, phd • Center for the Study of Nervous System Injury and Department of Neurology, Washington University School of Medicine, St. Louis, MO R. Spanagel • Central Institute of Mental Health, Mannheim, Germany Nobuyoshi Suto, ma • Department of Psychiatry, The University of Chicago, Chicago, IL David K. Thai, phd • Department of Pharmacology, University of Utah School of Medicine, Salt Lake City, UT

Louis Trevisan, md • Department of Psychiatry, Yale University School of Medicine, New Haven, CT; Alcohol Research Center, VA Connecticut Healthcare System, West Haven, CT Keith A. Trujillo, phd • Department of Psychology, California State University San

Marcos, San Marcos, CA Paul Vezina, phd • Department of Psychiatry, The University of Chicago, Chicago, IL John Q. Wang, md, phd • Division of Pharmacology, School of Pharmacy, University of Missouri-Kansas City, Kansas City, MO Forrest F. Weight, md • Division of Intramural Clinical and Biological Research, National Institute on Alcohol Abuse and Alcoholism (NIAAA), Bethesda, MD

Susan R. B. Weiss, PhD • Biological Psychiatry Branch, National Institute of Mental

Health, National Institutes of Health, Bethesda, MD Jeffrey M. Witkin, PhD • Neuroscience Discovery Research, Lilly Research Laboratories,

Lilly Corporate Center, Indianapolis, IN Marina E. Wolf, PhD • Department of Neuroscience, FUHS/The Chicago Medical

School, North Chicago, IL Bryan K. Yamamoto, PhD • Department of Pharmacology, Boston University School of Medicine, Boston, MA W. ZiEGLGÄNSBERGER, MD, PhD • Max-Planck Institute of Psychiatry, Munich, Germany Steven R. Zukin, md • DTRD, National Institute on Drug Abuse, Bethesda, MD

I Introduction

Natural Detox

Natural Detox

Are you looking for a full total body detox? If so, then you might want to try a 10 day detox or some refer to it as the 2-week detox. A 10-day detox is a full body detox that usually means taking several different steps to reach your total body transformation. It might involve a change in diet, exercise and more.

Get My Free Ebook


Post a comment